Search Results

Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinin of influenza virus strains representing the influenza viruses likely to circulate in Canada in the upcoming winter on the basis of the recommendations from the World Health Organization (WHO) and the National Advisory Committee on Immunization (NACI).

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/131-product-monograph--flucelvax-20222023.pdf

9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2022-23-afluria-tetra-product-monograph.pdf

As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2022-23-fluad-product-monograph.pdf

Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months

https://www.seqirus.ca/news/seqirus-receives-health-canada-approval-for-expanded-age-indication-for-people-as-young-as-6-months

Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.

https://www.seqirus.ca/

Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.

https://www.seqirus.ca/our-company

Seqirus Canada Commends U.S. ACIP Preferential Recommendation for Enhanced Flu Vaccines for Adults 65 and Older

https://www.seqirus.ca/news/seqirus-canada-commends-us-acip-preferential-recommendation--enhanced-flu-vaccines-adults-65-and-up

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.seqirus.ca/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.ca/news

Influenza vaccines are sold as non-returnable unless specified in a separate contract.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/seqirus-canada-inc-2022-may-terms-and-conditions-en-final.pdf